Bone Biologics Corp (BBLG): Price and Financial Metrics
BBLG Price/Volume Stats
| Current price | $1.80 | 52-week high | $72.00 |
| Prev. close | $1.77 | 52-week low | $1.56 |
| Day low | $1.67 | Volume | 92,900 |
| Day high | $1.94 | Avg. volume | 104,627 |
| 50-day MA | $2.49 | Dividend yield | N/A |
| 200-day MA | $4.97 | Market Cap | 958.53K |
BBLG Stock Price Chart Interactive Chart >
Bone Biologics Corp (BBLG) Company Bio
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Latest BBLG News From Around the Web
Below are the latest news stories about BONE BIOLOGICS CORP that investors may wish to consider to help them evaluate BBLG as an investment opportunity.
BBLG Announces Split as Pursuit of Breakthrough Treatment ContinuesBy Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT There are approximately 350,000 spinal fusion surgeries done in the US every year with varying degrees of success in alleviating often debilitating back pain. The existing dominant technology, known as rhBMP, has been quite successful in advancing the spinal fusion procedure but there are also challenges that can come along with |
Bone Biologics Announces 1-for-8 Reverse Stock SplitBURLINGTON, Mass., December 18, 2023--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8. The reverse stock split will take effect as of 12:01 a.m. ET, on Wednesday, December 20, 2023, and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol, |
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq RulesBURLINGTON, Mass., November 20, 2023--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share. In a concurrent private placement, the Company also issued and sold unregistered warrants to purchase up to an aggregate of 1,139,063 |
Dear LI Stock Fans, Mark Your Calendars for Dec. 4Li Auto stock fans are preparing for a major catalyst when the company's shares join the Hang Seng Index starting on Dec. |
Why Is Bone Biologics (BBLG) Stock Down 38% Today?Bone Biologics stock is falling on Friday as shares of BBLG give up some of the gains they saw during an unexpected rally on Thursday! |
BBLG Price Returns
| 1-mo | -25.00% |
| 3-mo | -44.62% |
| 6-mo | -62.51% |
| 1-year | -97.12% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -60.18% |
| 2023 | -91.02% |
| 2022 | -94.04% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...